cyclic heptapeptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-08-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analog of alpha-melanocyte-stimulating hormone |
| Primary receptor family | Melanocortin receptors MC1R through MC5R | Binding is not subtype-selective |
| Development period | 1980s | Synthesized during pigmentation and appetite research |
| Regulatory status | Not an approved medicine | No major regulator has authorized human use |
| Related compound | Afamelanotide | Linear analog studied for photoprotection |
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
GABAA receptor: positive allosteric modulator (primarily of δ subunit-containing receptors) NMDA receptor: negative allosteric modulator AMPA receptor: negative allosteric modulator Kainate receptor: negative allosteric modulator Glycine receptor: positive allosteric modulator Serotonin 5-HT3 receptor: positive allosteric modulator Opioid receptor: endogenous positive allosteric modulator Muscarinic acetylcholine receptor: positive allosteric modulator. Nicotinic acetylcholine receptor: positive allosteric modulator Glycine reuptake inhibitor Adenosine reuptake inhibitor L-type calcium channel: channel blocker GIRK: channel opener Voltage-gated calcium channel Dihydropyridine-sensitive L-type Ca2+ channels BK channel modulation G-protein-activated inwardly rectifying K+ channels Brain medulla: Decreased levels of nitric oxide Mesolimbic pathway: Increased levels of dopamine and endogenous opioids, secondary to other actions Many of these actions have been found to occur only at very high concentrations that may not be pharmacologically significant at recreational doses of ethanol, and it is unclear how or to what extent each of the individual actions is involved in the effects of ethanol. Some of the actions of ethanol on ligand-gated ion channels, specifically the nicotinic acetylcholine receptors and the glycine receptor, are dose-dependent, with potentiation or inhibition occurring dependent on ethanol concentration. This seems to be because the effects of ethanol on these channels are a summation of positive and negative allosteric modulatory actions.
== Composition == Silk is made up of two primary proteins; a fibrous protein known as fibroin, and a sticky protein known as sericin, with the two comprising 70–80% and 20–30% of silk, respectively. The source of these silk amino acids is typically the cocoons of the domestic silk moth, Bombyx mori, although other sources are known. Silk peptides are produced by acid hydrolysis of silk followed by neutralization of excess acid, filtration, and further processing steps to remove salts and other impurities followed by freeze drying. The resultant product contains a mixture of peptides typically between 2 and 20 amino acids in length, with a major component being the 18 amino acid fragment GAGAGSGAGAGSGAGAGS comprising three repeat units of the β‑sheet motif Gly-Ala-Gly-Ala-Gly-Ser derived from the repetitive crystalline domain of silk fibroin protein.
Dose dumping is a phenomenon of drug metabolism in which environmental factors can cause the premature and exaggerated release of a drug. This can greatly increase the concentration of a drug in the body and thereby produce adverse effects or even drug-induced toxicity. Dose dumping is most commonly seen in drugs taken by mouth and digested in the gastrointestinal tract. Around the same time patients take their medication, they can also ingest other substances like fatty meals or alcohol that increase drug delivery. The substances may act on the drug's capsule to speed up drug release, or they may stimulate the body's absorptive surfaces to increase the rate of drug uptake. Dose dumping is a disadvantage found in extended release dosage form. In general, drug companies try to avoid drugs with significant dose dumping effects. Such drugs are prone to problems and are often pulled from the market. Such was the case with the pain medication Palladone Once Daily formulation due to its dose-dumping effects when taken with alcohol.
In 2006 he finished the book Beyond the Setting Sun, with an introduction by Ranulph Fiennes, the renowned polar explorer and adventurer. The book was written to raise money for hospices in Britain, Canada and America.
For McArdle disease (GSD-V), regular aerobic exercise utilizing "second wind" to enable the muscles to become aerobically conditioned, as well as anaerobic exercise that follows the activity adaptations so as not to cause muscle injury, helps to improve exercise intolerance symptoms and maintain overall health. Studies have shown that regular low-moderate aerobic exercise increases peak power output, increases peak oxygen uptake (VO2peak), lowers heart rate, and lowers serum CK in individuals with McArdle disease. Regardless of whether the patient experiences symptoms of muscle pain, muscle fatigue, or cramping, the phenomenon of second wind having been achieved is demonstrable by the sign of an increased heart rate dropping while maintaining the same speed on the treadmill. Inactive patients experienced second wind, demonstrated through relief of typical symptoms and the sign of an increased heart rate dropping, while performing low-moderate aerobic exercise (walking or brisk walking). Conversely, patients that were regularly active did not experience the typical symptoms during low-moderate aerobic exercise (walking or brisk walking), but still demonstrated second wind by the sign of an increased heart rate dropping. For the regularly active patients, it took more strenuous exercise (very brisk walking/jogging or bicycling) for them to experience both the typical symptoms and relief thereof, along with the sign of an increased heart rate dropping, demonstrating second wind.
Sources: en.wikipedia.org
The car dealership Evans Halshaw is in Sunderland. The car factory owned by Nissan Motor Manufacturing UK between North Hylton and Washington is the largest in the UK. Grundfos, the world's leading pump manufacturer, builds pumps in Sunderland. Calsonic Kansei UK, formerly Magna, make automotive instrument panels and car trim at the Pennywell Industrial Estate. Gestamp UK make automotive components. Smith Electric Vehicles originated in Washington. The LG Electronics microwave oven factory opened in 1989, closed in May 2004, and later became the site of the Tanfield Group. Goodyear Dunlop had their only UK car tyre factory next to the Tanfield site until its 2006 closure. BAE Systems Global Combat Systems moved to a new £75 million factory at the former Goodyear site in 2011, where they make large calibre ammunition for tanks and artillery. The government's child benefit office is in Washington. Liebherr build cranes next to the Wear at Deptford. The outdoor clothing company Berghaus is in Castletown. Vaux Breweries, who owned Swallow Hotels, closed in 1999. ScS Sofas are on Borough Road. There are many call centres in Sunderland, notably EDF Energy at the Doxford International Business Park, which is also the home of the headquarters of the large international transport company Arriva and Nike UK. Rolls-Royce planned to move their production of fan and turbine discs to BAE Systems' new site in 2016.
Includes the perirhinal and entorhinal cortices. Rhombencephalon Also known as the hindbrain, this embryonic brain region gives rise to the pons, medulla oblongata, and cerebellum. Ribosome A cellular organelle responsible for protein synthesis. In neurons, local ribosome activity occurs in dendrites and axons, supporting synaptic plasticity. Rostral A directional term meaning “toward the nose” or front of the brain. Often used in anatomical descriptions of the central nervous system. Ruffini ending A slow-adapting mechanoreceptor found in the skin that detects skin stretch and contributes to proprioception and object manipulation. RUNX1 A transcription factor involved in sensory neuron differentiation and pain signaling. Active during embryonic development and in peripheral nervous system patterning.
Probable UIP pattern: Predominantly subpleural and basal Often heterogenous distribution Reticular pattern with peripheral traction bronchiectasis or bronchiolectasis There may be mild ground-glass opacity Indeterminate for UIP: Predominantly subpleural and basal Subtle reticular pattern May have mild ground-glass opacity or distortion (“early UIP pattern”) Findings suggestive of another diagnosis, including: Other predominant distribution: Peribronchovascular Perilymphatic Upper or mid-lung Cysts Marked mosaic pattern Predominant ground-glass opacity Profuse lung micronodules Lung nodules, especially centrilobular Consolidation Pleural plaques (indicating asbestosis) Dilated esophagus (indicating connective tissue disease) Distal clavicular erosions (indicating rheumatoid arthritis) Extensive lymph node enlargement Pleural effusion Pleural thickening (indicating connective tissue disease/drugs)
Inflammation of the pericardium is called pericarditis. This condition typically causes chest pain that spreads to the back and is made worse by lying flat. In patients suffering with pericarditis, a pericardial friction rub can often be heard when listening to the heart with a stethoscope. Pericarditis is often caused by a viral infection (glandular fever, cytomegalovirus, or coxsackievirus), or more rarely with a bacterial infection, but may also occur following a myocardial infarction. Pericarditis is usually a short-lived condition that can be successfully treated with painkillers, anti-inflammatories, and colchicine. In some cases, pericarditis can become a long-term condition causing scarring of the pericardium which restricts the heart's movement, known as constrictive pericarditis. Constrictive pericarditis is sometimes treated by surgically removing the pericardium in a procedure called a pericardiectomy. Fluid can build up within the pericardial space, referred to as a pericardial effusion. Pericardial effusions often occur secondary to pericarditis, kidney failure, or tumours and frequently do not cause any symptoms. Large effusions or effusions that accumulate rapidly can compress the heart and restrict diastolic ventricular filling in a condition known as cardiac tamponade, causing pulsus paradoxus and potentially fatal circulatory failure. Fluid can be removed from the pericardial space for diagnosis or to relieve tamponade using a syringe in a procedure called pericardiocentesis.
Sources: en.wikipedia.org
No regulator in a major market has approved it for human use. It appears in research settings and in products marketed outside pharmacy channels. Legal status for personal possession varies by country.
Afamelanotide is a linear analog that has received approval in some jurisdictions for a specific photoprotection indication. Melanotan II is cyclic and less selective across melanocortin receptors. The two are related but are not interchangeable in regulatory or clinical terms.
A compound that activates several receptor subtypes may produce effects beyond pigmentation. Selectivity influences which tissues respond and shapes the side-effect profile described in reports. Designing subtype-selective analogs is a stated goal of melanocortin research.
It is a synthetic cyclic heptapeptide and a non-selective melanocortin receptor agonist. Structurally it is modelled on alpha-melanocyte-stimulating hormone, a peptide that occurs naturally in the body.